The Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV). The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The Abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic leukemia (CML), 20-25% of adult acute lymphoblastic leukemia (ALL) and 2-5% of pediatric ALL. In these leukemias the c-Abl proto-oncogene undergoes a (9;22) chromosomal translocation producing the Philadelphia (Ph1) chromosome. The molecular consequence of this trans-location is the generation of a chimeric Bcr/c-Abl mRNA encoding activated Abl protein-tyrosine kinase. The Bcr gene has been shown to encode a GTPase-activating protein (GAP) specific for the Ras-related GTP-binding protein, p21rac.
Key Feature
Clonality
Polyclonal
Isotype
IgG
Host Species
Rabbit
Tested Applications
IFIHC
recommended for detection of Tyr 412 phosphorylated c-Abl isoform IB and correspondingly phosphorylated Tyr 393 c-Abl isoform IA of mouse and human origin by IF and IHC(P)
Species Reactivity
HumanMouseRat
Concentration
1mg/ml
Purification
Affinity purified
Target Information
Alternative Names
epitope corresponding to phosphorylated c-Abl isoform 2 of human origin
Tissue Specificity
epitope corresponding to phosphorylated c-Abl isoform 2 of human origin
Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing cytoplasmic staining.
Application Notes
recommended for detection of Tyr 412 phosphorylated c-Abl isoform IB and correspondingly phosphorylated Tyr 393 c-Abl isoform IA of mouse and human origin by IF and IHC(P)
Additional Information
Form
Liquid
Storage Instructions
For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.